Rheumatic fever and long-term use of benzathine penicillin as possible risk factors for extensive macular atrophy with pseudodrusen in a Brazilian cohort

• Published in: International journal of retina and vitreous 2024-10, Vol.10 (1), p.75-9, Article 75
• Main Authors: Moreira-Neto, Carlos Augusto, Schmidt Andujar, Rafaella Atherino, Chao, John Chii Tyng, Vasconcelos, Huber, Alves, Fábio Eduardo Eberhardt, Rodrigues, Gabriela Doná, Hirt, Bruno, Arana, Jayme, Souza, Eduardo Cunha, Maia, André, Sallum, Juliana Maria Ferraz, Moreira, Jr, Carlos Augusto
• Format: Article
• Language: English
• Subjects: Benzathine penicillin; Electroretinography; EMAP; Extensive macular atrophy with pseudodrusen-like appearance; Macular atrophy; Rheumatic fever
• ISSN: 2056-9920; 2056-9920
• DOI: 10.1186/s40942-024-00592-y

Although there has been a large increase in the number of extensive macular atrophy with pseudodrusen (EMAP) cases, the basic aspects of this disease remain unknown. Brazilian patients have a common past history of rheumatic fever (RF) and/or benzathine penicillin (BP) treatment possibly related to the disease. We analyzed how RF and BP might be correlated with EMAP in Brazilian patients. Observational, retrospective, case-control study. The databases of three private eye clinics in Brazil were searched for patients with an EMAP-like appearance. Each patient was asked about a previous history of RF and/or long-term use of BP. Patients underwent best-corrected visual acuity (BCVA) measurement, color fundus imaging, fundus autofluorescence (FAF) imaging, optical coherence tomography (OCT) imaging, and electroretinography (ERG). The following characteristics were analyzed: subretinal drusenoid deposits (SDD), pigment mottling, retinal pigment epithelial/basement membrane (RPE/BM) separation, outer retinal or RPE atrophy, and identification of a paving stone-like appearance. The choroidal thickness was measured using enhanced depth imaging OCT. The central atrophic area was measured manually on ultra-wide-field FAF. A total of 154 eyes of 77 patients (women, 66.2%; mean age, 58.6 years) with EMAP were included; 90.9% of patients were diagnosed with RF; 94.8% had been treated with BP and treatment was started at an average age of 7.3 years (mean duration, 11.8 years). The treatment duration was significant for the area of atrophy (P = 0.027) in which each 1-year increase in treatment duration led to an average reduction of 6.91 mm in area. The age at diagnosis of RF was significant (P = 0.026) for SDD. The increase of 1 year in the diagnosis of RF (late disease) led to a reduction of 24% in the chance of central SDD being present. On OCT, 65.5% eyes had SDD and more than 70% had a split RPE/BM and outer retinal or RPE atrophy. The choroidal thickness in patients with EMAP was significantly (P